These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36680283)

  • 41. Omicron new variant BA.2.86 (Pirola): Epidemiological, biological, and clinical characteristics - a global data-based analysis.
    Meo SA; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9470-9476. PubMed ID: 37843359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot Study.
    Aoki A; Adachi H; Mori Y; Ito M; Sato K; Okuda K; Sakakibara T; Okamoto Y; Jinno H
    Microbiol Spectr; 2022 Aug; 10(4):e0136722. PubMed ID: 35861527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5.
    Torres C; Nabaes Jodar M; Acuña D; Montaño RMZ; Culasso ACA; Amadio AF; Aulicino P; Ceballos S; Cacciabue M; Debat H; Dus Santos MJ; Eberhardt MF; Espul C; Fay F; Fernández MA; Fernández F; Muñoz JMF; Ferrini F; Gallego F; Giri AA; Cerri A; Bolatti E; Gismondi MI; Goya S; Gramundi I; Irazoqui JM; König GA; Leiva V; Lucero H; Marquez N; Nardi C; Ortiz B; Pianciola L; Pintos CB; Puebla AF; Rastellini CV; Rojas AE; Sfalcin J; Suárez A; Tittarelli E; Toro R; Villanova GV; Ziehm MC; Zimmermann MC; Zunino S; Proyecto Pais Working Group ; Valinotto L; Viegas M
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evolution of the spike protein and hACE2 interface of SARS-CoV-2 omicron variants determined by hydrogen bond formation.
    Yang YY; Tseng YJ
    Brief Funct Genomics; 2023 May; 22(3):291-301. PubMed ID: 36723978
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.
    Sarkar A; Omar S; Alshareef A; Fanous K; Sarker S; Alroobi H; Zamir F; Yousef M; Zakaria D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2212568. PubMed ID: 37254497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021-22: a status-based multi-variant model.
    Haschka T; Vergu E; Roche B; Poletto C; Opatowski L
    BMC Infect Dis; 2022 Nov; 22(1):815. PubMed ID: 36324075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants.
    Lee JE; Hwang M; Kim YH; Chung MJ; Jeong WG; Sim BH; Jeong YJ
    Radiology; 2023 Jul; 308(1):e230653. PubMed ID: 37462497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis.
    Relan P; Motaze NV; Kothari K; Askie L; Le Polain O; Van Kerkhove MD; Diaz J; Tirupakuzhi Vijayaraghavan BK
    BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37419502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Airborne virus shedding of the alpha, delta, omicron SARS-CoV-2 variants and influenza virus in hospitalized patients.
    Ong DSY; de Man P; Verhagen T; Doejaaren G; Dallinga MA; Alibux E; Janssen ML; Wils EJ
    J Med Virol; 2023 Apr; 95(4):e28748. PubMed ID: 37185846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity.
    Zhou Y; Zhi H; Teng Y
    J Med Virol; 2023 Jan; 95(1):e28138. PubMed ID: 36097349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.
    Tian D; Nie W; Sun Y; Ye Q
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immediate reinfection with Omicron variant after clearance of a previous SARS-CoV-2 infection.
    Mencacci A; Gili A; Camilloni B; Bicchieraro G; Spaccapelo R; Bietta C; Stracci F
    J Infect Public Health; 2022 Sep; 15(9):983-985. PubMed ID: 35963101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nursing and healthcare-associated pneumonia due to SARS-CoV-2 Omicron variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Respir Investig; 2024 Mar; 62(2):252-257. PubMed ID: 38241958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 from COVID-19 Patients in the Republic of Moldova: Whole-Genome Sequencing Results.
    Morozov A; Nirca V; Victorova A; Poppert S; Frickmann H; Yamada C; Kacena MA; Rata S; Movila A
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants.
    Qu P; Evans JP; Kurhade C; Zeng C; Zheng YM; Xu K; Shi PY; Xie X; Liu SL
    mBio; 2023 Feb; 14(1):e0317622. PubMed ID: 36625591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.